Wedbush Reiterates Outperform on Cidara Therapeutics (CDTX) Following 2Q

Wedbush reiterated an Outperform rating and $22.00 price target on Cidara Therapeutics (NASDAQ: CDTX) following the company's 2Q. CDTX reported a net loss of ($11.9M) or ($0.85)/share, below the consensus of ($0.76), on higher than expected R&D costs.

Analyst David Nierengarten commented, "With CD101 demonstrating potent antifungal activity in animal studies, and Ph 1 trials confirming improved PK, we see a high probability of success for CD101’s Ph 2 program."

For an analyst ratings summary and ratings history on Cidara Therapeutics click here. For more ratings news on Cidara Therapeutics click here.

Shares of Cidara Therapeutics closed at $11.98 yesterday.

You May Also Be Interested In

• Cidara Therapeutics (CDTX) PT Raised to $25 at Needham
• Merck (MRK) PT Raised to $143 at Truist Securities
• Cidara Therapeutics (CDTX) Announces Divestiture of Rezafungin to Mundipharma